Immunogenicity and safety profiles of a new MAV/06 strain varicella vaccine in healthy children: A multinational, multicenter, randomized, double-blinded, active-controlled phase III study.
Children
Double blind
Immunogenicity
MAV/06 strain
Multicenter
Multinational
Phase 3 Clinical trial
Safety
Varicella Vaccine
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
19 03 2021
19 03 2021
Historique:
received:
23
08
2020
revised:
12
01
2021
accepted:
06
02
2021
pubmed:
26
2
2021
medline:
25
5
2021
entrez:
25
2
2021
Statut:
ppublish
Résumé
Immunization is the most effective preventive strategy against varicella. While the Oka strain is commonly used for varicella vaccination worldwide, Korea widely uses the MAV/06 strain. A new live attenuated MAV/06 strain varicella vaccine (MG1111), which uses the new cell line Medical Research Council-5 for better viral propagation, was developed. MG1111 was approved by Korean health authorities. Here, we report the results of phase III, randomized, double-blind, multicenter study conducted in Korea and Thailand, which compared the immunogenicity and safety profiles of MG1111 versus the control vaccine, Varivax
Identifiants
pubmed: 33627245
pii: S0264-410X(21)00161-4
doi: 10.1016/j.vaccine.2021.02.013
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Chickenpox Vaccine
0
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1758-1764Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.